CNBC’s David Faber and Carl Icahn, chairman, Icahn Enterprises LP (NASDAQ:IEP), discuss corporate boards, a dysfunctional system, his impact as an activist investor and why what he does is important, as well as the use of poison pills to fend off activists. He also finds himself in the unusual position of defending Bill Ackman’s recent efforts to partner with Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and acquire Allergan, Inc. (NYSE:AGN).
About the Author
Sheeraz is our COO (Chief - Operations), his primary duty is curating and editing of ValueWalk. He is main reason behind the rapid growth of the business. Sheeraz previously ran a taxation firm. He is an expert in technology, he has over 5.5 years of design, development and roll-out experience for SEO and SEM. - Email: sraza(at)valuewalk.com